Tandem Diabetes Care, Inc. (TNDM) Financial Statements (2024 and earlier)

Company Profile

Business Address 12400 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments507,246519,588616,901608,727635,331635,391
Cash and cash equivalents130,751127,762172,517123,786114,96693,681
Short-term investments376,495391,826444,384484,941520,365541,710
Receivables98,71491,393114,717112,805103,76394,133
Inventory, net of allowances, customer advances and progress billings147,599131,557111,117104,77488,09879,987
Inventory147,599131,557111,117104,77488,09879,987
Other undisclosed current assets10,74515,3817,2417,9977,8528,953
Total current assets:764,304757,919849,976834,303835,044818,464
Noncurrent Assets
Operating lease, right-of-use asset91,054104,743110,626116,474126,672131,058
Property, plant and equipment73,75274,57868,55272,90558,90149,987
Other noncurrent assets17,56616,90523,63123,83815,95815,768
Total noncurrent assets:182,372196,226202,809213,217201,531196,813
TOTAL ASSETS:946,676954,1451,052,7851,047,5201,036,5751,015,277
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities70,20065,70865,325117,39693,70089,961
Employee-related liabilities47,96735,42938,258
Accounts payable57,08055,23155,73061,53150,66145,341
Accrued liabilities13,12010,4779,5957,8987,6106,362
Deferred revenue23,40120,76418,83712,97411,71310,881
Other liabilities27,82430,13929,32531,14023,92122,893
Other undisclosed current liabilities53,23054,54651,80312,1209,9258,080
Total current liabilities:174,655171,157165,290173,630139,259131,815
Noncurrent Liabilities
Long-term debt and lease obligation284,128283,679283,232409,896412,147411,100
Long-term debt, excluding current maturities284,128283,679283,232282,787282,345281,905
Liabilities, other than long-term debt158,659160,556164,31642,17235,58534,980
Deferred revenue15,30515,88616,87419,14318,34317,531
Other liabilities24,95423,80323,91823,02917,24217,449
Operating lease, liability118,400120,867123,524127,109129,802129,195
Total noncurrent liabilities:442,787444,235447,548452,068447,732446,080
Total liabilities:617,442615,392612,838625,698586,991577,895
Equity
Equity, attributable to parent329,234338,753439,947421,822449,584437,382
Common stock656565646464
Additional paid in capital1,219,1991,191,8431,170,8881,140,1581,118,1681,089,689
Accumulated other comprehensive loss(1,193)(93)(1,817)(5,064)(4,282)(3,061)
Accumulated deficit(888,837)(853,062)(729,189)(713,336)(664,366)(649,310)
Total equity:329,234338,753439,947421,822449,584437,382
TOTAL LIABILITIES AND EQUITY:946,676954,1451,052,7851,047,5201,036,5751,015,277

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues195,917169,383220,501204,547200,262175,907
Cost of revenue
(Cost of Goods and Services Sold)
(94,182)(86,476)(104,979)(100,122)(98,316)(84,814)
Gross profit:101,73582,907115,522104,425101,94691,093
Operating expenses(140,543)(210,724)(133,300)(151,918)(114,185)(106,431)
Operating loss:(38,808)(127,817)(17,778)(47,493)(12,239)(15,338)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
4,1794,2311,664144(711)(1,101)
Interest and debt expense(1,605)(1,634)(1,579)(1,576)(1,537)(1,516)
Loss from continuing operations before equity method investments, income taxes:(36,234)(125,220)(17,693)(48,925)(14,487)(17,955)
Other undisclosed income from continuing operations before income taxes1,6051,6341,5791,5761,5371,516
Loss from continuing operations before income taxes:(34,629)(123,586)(16,114)(47,349)(12,950)(16,439)
Income tax expense (benefit)(1,146)(287)261(1,621)(2,106)1,724
Loss from continuing operations:(35,775)(123,873)(15,853)(48,970)(15,056)(14,715)
Loss before gain (loss) on sale of properties:(48,970)(15,056)(14,715)
Net loss available to common stockholders, basic:(35,775)(123,873)(15,853)(48,970)(15,056)(14,715)
Dilutive securities, effect on basic earnings per share    12100 
Other undisclosed net loss available to common stockholders, diluted   (100)   
Net loss available to common stockholders, diluted:(35,775)(123,873)(15,953)(48,958)(14,956)(14,715)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(35,775)(123,873)(15,853)(48,970)(15,056)(14,715)
Comprehensive loss:(35,775)(123,873)(15,853)(48,970)(15,056)(14,715)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,100)1,7243,247(782)(1,221)(2,445)
Comprehensive loss, net of tax, attributable to parent:(36,875)(122,149)(12,606)(49,752)(16,277)(17,160)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: